Is consolidation with anti-CD30 CAR T-cell therapy well-tolerated and effective after autologous hematopoietic stem cell transplantation in patients with high-risk CD30+ #lymphoma ? Read our summary of results here: loom.ly/zG3DGWU

#lymsm #MedicalEducation

🚨 New account alert! 🚨

We now have an Instagram account: @lymphoma_hub

Follow us and keep an eye out for all the exciting content coming soon!

#lymphoma #lymsm #ChronicLymphocyticLeukemia #MedNews #MedEducation

Is acalabrutinib in combination with lenalidomide and rituximab well tolerated and effective in patients with R/R aggressive B-cell non-Hodgkin lymphoma?

Read our summary of results from a phase II trial: loom.ly/tDiaoMY.

#lymphoma #lymsm #MedicalEducation

🚨 NEWS 🚨
U.S. FDA grants accelerated approval to lisocabtagene maraleucel for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on response data from the phase II TRANSCEND FL trial 👉 loom.ly/BKk-2FM

#lymphoma #MedNews

Is nivolumab plus brentuximab vedotin an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma? Read our summary here: 👉 loom.ly/BLdgd1U.

#lymsm #lymphoma #MedicalEducation

Can machine learning-based survival prediction models improve prognostication in patients with advanced-stage Hodgkin lymphoma? Find out more here: loom.ly/D55EuNw

#lymsm #lymphoma #MedicalEducation

Is axicabtagene ciloleucel an effective treatment vs chemoimmunotherapy in older patients and/or patients with a poor ECOG Performance Status with R/R LBCL after ≥2 previous lines of therapy?

Find out here: loom.ly/G1gEj8s

#lymsm #lymphoma #LBCL

Is the addition of nivolumab to anti-CD19 CAR T-cell therapy well tolerated and effective in patients with progressive DLBCL?

Read our summary of results from a phase II trial here: loom.ly/JKeceK4

#lymsm #lymphoma #EBMT2024

Are anti-CD19 CAR T-cell therapies safe and effective in patients with primary or secondary CNS lymphoma? Read our summary of an analysis of this patient population: loom.ly/K5uKA6w

#lymphoma #lymsm #EBMT2024

🚨 NEWS 🚨
Positive results announced from the phase III ECHO trial (NCT02972840) of acalabrutinib plus bendamustine and rituximab in adult patients aged ≥65 years (n = 598) with previously untreated MCL. This combination demonstrated a statistically significant and clinically

Is camrelizumab in combination with gemcitabine and oxaliplatin an effective salvage regimen for patients with relapsed/refractory classical Hodgkin lymphoma?

Read our summary of results from a phase II trial: loom.ly/paVgt8Q

#lymsm #lymphoma #MedEducation

🎥 The Lymphoma Hub and Multiple Myeloma Hub were pleased to speak to Anna Sureda.

We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?

Watch here: loom.ly/hjUx93Y
#mmsm #myeloma #lymphoma #lymsm

Visit IWMF, booth 3047, April 25-27, at the ONS Congress in Washington, DC. Learn about our nursing and patient education resources. iwmf.com/publications/
#ONSCongress

🚨 New account alert! 🚨

We now have an Instagram account: @lymphoma_hub

Follow us and keep an eye out for all the exciting content coming soon!

#lymphoma #lymsm #ChronicLymphocyticLeukemia #MedNews #MedEducation

What are the patient-reported outcomes of liso-cel as a second-line treatment in patients with relapsed/refractory LBCL?

Read our summary of the patient-reported outcomes from the phase II PILOT study 👉 loom.ly/xuR4x08

#lymsm #lymphoma

Can measurable residual disease status at the end of induction predict event-free survival outcomes in pediatric T-cell lymphoblastic lymphoma?

Read our latest article to learn more: loom.ly/4Zw1agQ

#lymphoma #lymsm #MedEducation